Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Occupants in buildings can be exposed to fungal spores, cell fragments, or mycotoxins which can arise from a host of means, but there are two common classes: (a) excess moisture induced growth of mold colonies and (b) natural substances released into the air such as animal dander and plant pollen. While mold growth is associated with high moisture levels, it is likely to grow when a combination of favorable conditions arises. As well as high moisture levels, these conditions include suitable temperatures, pH and nutrient sources. Mold grows primarily on surfaces, and it reproduces by releasing spores, which can travel and settle in different locations. When these spores experience appropriate conditions, they can germinate and lead to mycelium growth. Different mold species favor different environmental conditions to germinate and grow, some being more hydrophilic (growing at higher levels of relative humidity) and other more xerophilic (growing at levels of relative humidity as low as 75–80%). Mold growth can be inhibited by keeping surfaces at conditions that are further from condensation, with relative humidity levels below 75%. This usually translates to a relative humidity of indoor air below 60%, in agreement with the guidelines for thermal comfort that recommend a relative humidity between 40 and 60%.
After the memo began circulating on the internet, Baidu denounced, in a communiqué on 13 September 2008, the approaches by said agency on several occasions, saying the proposal was firmly rejected, as it violated their corporate principles of unbiased and transparent reporting. New Zealand Prime Minister Helen Clark said that she believed the Chinese government had been inclined to try to solve the problem quietly, without a recall. According to the Hong Kong-based South China Morning Post, a 21-point coverage directive issued by the Central Propaganda Department to domestic media includes this edict: "All food safety issues [are] off-limits." Some media outlets speculated that China's desire for a perfect summer Olympics contributed to the delayed recall of the baby milk, citing the 21-point coverage directive. The Central government denied issuing this guidance. Hebei provincial vice-governor said his administration was only notified by Shijiazhuang on 8 September. However, a journalist at Southern Weekend wrote an investigative report in late July for publication about infants who had fallen ill after consuming baby formula from Sanlu. Six weeks later, senior editor Fu Jianfeng made a post on his personal blog stating that this report had been suppressed by authorities because of the imminent Beijing Olympics. While this was happening, Sanlu was honoured in a national award campaign called "30 Years: Brands that Have Changed the Lives of Chinese".
== Advantages of inlet ionization == Ionization at atmospheric pressure often leads to a loss of ions during the transfer of the ions from the ambient pressure region to the vacuum of the mass analyzer. Ions are lost due to dispersion of analyte spray and 'rim loss' causing fewer ions to reach the vacuum for m/z separation to occur. Initial ionization occurs in the sub-atmospheric pressure region of the heated inlet tube which is directly attached to the vacuum of the mass analyzer and so ion loss is reduced as transfer of the ions does not occur. In LSII the use of the laser increases the image quality of the results by producing better spatial resolution. This is where more pixels are created and so a clearer image is obtained. Multiply charged ions are produced further extending mass range. Multiple methods can be used to fragment molecules producing fragmentation for structural information: electron transfer dissociation (ETD), collision-induced dissociation (CID), and electron capture dissociation (ECD). When using a laser, only small volumes are needed.
In October 2025, Moore blamed Trump for the 2025 United States federal government shutdown while urging him to end the shutdown, saying that Maryland would likely face "serious damage" as the shutdown continued through infrastructure project delays, federal employees not receiving pay, and small businesses losing revenue. At the same time, he said that he would work with state companies to protect federal workers impacted by the government shutdown and directed state agencies to deploy contingency plans to keep federally funded programs continually operating. Moore initially declined to provide state funding to fund the Supplemental Nutrition Assistance Program (SNAP) after the U.S. Department of Agriculture (USDA) declined to use its contingency fund to continue funding SNAP, but later signed an order declaring a state of emergency and providing $10 million in funds to assist food banks across Maryland. After the Trump administration said it would only partially fund SNAP food benefits following a federal court ruling ordering it to pay SNAP benefits out of the USDA's contingency fund, Moore signed an executive order providing $62 million in state funds to provide SNAP participants with full benefits during the month of November. In November 2025, Moore criticized the bipartisan Senate agreement to end the shutdown, saying that it was "completely unacceptable" to pass a bill ending the shutdown without extending healthcare subsidies.
=== Former hospitals === Former UPMC hospitals include UPMC Sunbury in Sunbury, Pennsylvania (2017–2020) which was closed and services integrated into other nearby facilities; UPMC Beacon Hospital in Dublin, Ireland (2009 to 2014) which was acquired by Irish businessman Denis O'Brien; UPMC Braddock in Braddock, Pennsylvania (1996 to 2010) which was closed; UPMC South Side hospital in Pittsburgh (1996 to 2009) which was merged with UPMC Mercy and converted into UPMC Mercy South Side Outpatient Center; UPMC Lee Regional in Johnstown, Pennsylvania (1998 to 2005) which was sold to Conemaugh Health System; and UPMC Beaver Valley in Aliquippa, Pennsylvania (1996 to 2001) which was transferred back to its community board and subsequently closed. UPMC Pinnacle Lancaster, formerly St. Joseph's hospital in Lancaster, Pennsylvania, closed on February 28, 2019, and its services were consolidated into UPMC Pinnacle Lititz.
Sources: en.wikipedia.org
== History == Pentazocine was developed by the Sterling Drug Company, Sterling-Winthrop Research Institute, of Rensselaer, New York. The analgesic compound was first made at Sterling in 1958. U.S. testing was conducted between 1961 and 1967. It was approved by the Food and Drug Administration in June 1967 after being favorably reviewed following testing on 12,000 patients in the United States. By mid 1967 Pentazocine was already being sold in Mexico, England, and Argentina, under different trade names.
=== Absorption === Bicalutamide is extensively and well-absorbed following oral administration, and its absorption is not affected by food. The absolute bioavailability of bicalutamide in humans is unknown due to its very low water solubility and hence lack of an assessable intravenous formulation. However, the absolute bioavailability of bicalutamide has been found to be high in animals at low doses (109% in mice at 10 mg/kg; 72% in rats at 1 mg/kg; 100% in dogs at 0.1 mg/kg), but diminishes with increasing doses such that the bioavailability of bicalutamide is low at high doses (10% in rats at 250 mg/kg; 31% in dogs at 100 mg/kg). In accordance, absorption of (R)-bicalutamide in humans is slow and extensive but saturable, with steady-state levels increasing linearly at a dosage of up to 150 mg/day and non-linearly at higher dosages. At higher dosages of 100 to 200 mg/day, absorption of bicalutamide is approximately linear, with a small but increasing departure from linearity above 150 mg/day. In terms of geometric mean steady-state concentrations of (R)-bicalutamide, the departures from linearity were 4%, 13%, 17%, and 32% with dosages of 100, 150, 200, and 300 mg/day, respectively. There is a plateau in steady-state levels of (R)-bicalutamide with bicalutamide dosages above 300 mg/day, and, accordingly, dosages of bicalutamide of 300 to 600 mg/day result in similar circulating concentrations of (R)-bicalutamide and similar degrees clinically of efficacy, tolerability, and toxicity.
In September 2025, Eucalyptus introduced an AI chatbot prompting warning from professional bodies about the use of artificial intelligence in weight-loss programs. In late December 2025, peak eating disorder advocacy groups expressed concerns about the rapid rollout of GLP-1 weight-loss treatments alongside their aggressive marketing on social media. There were concerns from The Australia and New Zealand Academy for Eating Disorders that these marketing techniques could target people who do not need the medication. Juniper's Black Friday sale was one of the marketing practices in question.
=== pH buffering === The pH of the mobile phase can change the retention and selectivity of analytes. For samples containing solutes with ionized functional groups, such as amines, carboxyls, phosphates, phosphonates, sulfates, and sulfonates, the ionization of these groups can be controlled by controlling the pH of the mobile phase. The pH of the mobile phase can be controlled by mobile phase buffers. In general, molecules with acidic function groups are increasingly ionized under more alkaline environments, and thus its retention time would decrease. Conversely, under more acidic environments, its retention time would increase. Conversely for molecules with alkaline function groups. For example, carboxylic groups in solutes become increasingly negatively charged as the pH of the mobile phase rises above their pKa, hence the whole molecule becomes more polar and less retained on the a-polar stationary phase. In this case, raising the pH of the phase mobile above 4–5 = pH (which is the typical pKa range for carboxylic groups) increases their ionization, hence decreases their retention. Similarly, molecules with amine groups usually have pKa around 8. However, since silica gel is not stable in alkaline environments, the mobile phase typically does not have pH above 8. Therefore, control over the retention of amines is limited when the stationary phase is based on silica gel. The choice of buffer type is an important factor in RP-LC method development, as it can affect the retention, selectivity, and resolution of the analytes of interest.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.